Projects and Grants per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Doctor of Medicine, University Of Kentucky
2008
Doctor of Philosophy, University Of Kentucky
2008
Bachelor of Science, University Of Kentucky
2000
Bachelor of Arts, University Of Kentucky
2000
Fingerprint
Dive into the research topics where Mark Wurth is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration from the last 5 years on country level. Dive into details by clicking on the dots.
-
Therapeutics Development Center FY26
Wurth, M. (PI), Anstead, M. (CoI), Autry, E. (CoI), Cosentino Roa, M. (CoI), Kanga, J. (CoI), Kormelink, L. (CoI) & Ramdial, F. (CoI)
7/1/25 → 6/30/26
Project: Research project
-
Cystic Fibrosis Center Program FY26 - Pediatrics Portion
Kanga, J. (PI), Anstead, M. (CoI), Cosentino Roa, M. (CoI), Fuller, W. (CoI), Marsac, M. (CoI), Ramdial, F. (CoI), Thomas, T. (CoI) & Wurth, M. (CoI)
7/1/25 → 6/30/26
Project: Research project
-
A Phase 1 Study of VX-828 in Healthy Subjects and in Subjects with Cystic Fibrosis (VX23-828-001)
Wurth, M. (PI), Anstead, M. (CoI), Cosentino Roa, M. (CoI) & Ramdial, F. (CoI)
6/18/25 → 6/18/27
Project: Research project
-
PSK05: A Phase 3, Randomized, Modified Double-Blind, Active-Controlled, Parallel-Group, 2-Arm Study to Investigate the Safety of a 4-Dose Regimen of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers
Wurth, M. (PI), Davies, T. (CoI) & Howard, J. (CoI)
6/12/25 → 6/12/27
Project: Research project
-
AZALEA: A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
DeFranco, E. (PI), Giannone, P. (CoI) & Wurth, M. (CoI)
Janssen Research and Development LLC
4/25/25 → 4/25/27
Project: Research project
-
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
VX20-121-102 Study Group & VX20-121-103 Study Group, Mar 2025, In: The Lancet Respiratory Medicine. 13, 3, p. 256-271 16 p.Research output: Contribution to journal › Article › peer-review
Open Access46 Scopus citations -
Tissue plasminogen activator associated pulmonary hemorrhage in patient with ACTA2-associated arteriopathy
Hughes, T. G., Wurth, M. A. & Sheppard, M. B., Dec 2024, In: Journal of Vascular Surgery Cases, Innovations and Techniques. 10, 6, 101558.Research output: Contribution to journal › Article › peer-review
Open Access -
CFTR modulator drug desensitization: Preserving the hope of long term improvement
Leonhardt, K., Autry, E. B., Kuhn, R. J. & Wurth, M. A., Aug 2021, In: Pediatric Pulmonology. 56, 8, p. 2546-2552 7 p.Research output: Contribution to journal › Article › peer-review
23 Scopus citations -
Opportunities to support emotional health in school-age children with food allergy
Marsac, M. L. & Wurth, M. A., Jun 2021, In: Annals of Allergy, Asthma and Immunology. 126, 6, p. 728-729 2 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis
Saad, A., Young, M. R., Studtmann, A. E., Autry, E. B., Schadler, A., Beckman, E. J., Gardner, B. M., Wurth, M. A. & Kuhn, R. J., Dec 2020, In: Pediatric Pulmonology. 55, 12, p. 3384-3390 7 p.Research output: Contribution to journal › Article › peer-review
12 Scopus citations